Botox for Chronic Migraine: Benefits, Safety, and What to Expect
An evidence-based guide to onabotulinumtoxinA for eligible adults with chronic migraine—including who may benefit, what the studies show, how treatment is performed, and the risks that should be discussed before treatment.
What Botox is—and what it is not
Botox® is the brand name for onabotulinumtoxinA, a prescription botulinum neurotoxin type A. For chronic migraine, it is injected into specific head and neck locations on a repeating schedule. It is the same active product used for some cosmetic and other neurological indications, but the diagnosis, dose, injection pattern, treatment goals, and medical monitoring are different.
Botox is not a dermal filler, and it is not an acute rescue medication. Its role is prevention: reducing headache frequency, severity, disability, or reliance on acute medication in appropriately selected adults. A benefit is possible, but not guaranteed, and complete elimination of migraine is not the usual expectation.
Evidence cutoff: This page reflects U.S. prescribing information, guidelines, and publicly available evidence through July 10, 2026. Regulatory indications, payer policies, and safety information can change.
Chronic migraine diagnosis and the FDA indication are related—but not identical
The clinical diagnosis uses international criteria. The medication label uses its own wording. Insurance plans may add separate documentation rules.
Clinical diagnosis
ICHD-3 chronic migraine
- Headache on 15 or more days per month for more than 3 months.
- On at least 8 days per month, the headache has migraine features or responds as migraine to a triptan or ergot.
- Another diagnosis does not better explain the pattern.2
U.S. label
FDA-approved migraine use
- Prevention of headaches in adults with chronic migraine.
- The label describes 15 or more headache days per month, with headache lasting 4 hours a day or longer.1
- The label does not require failure of a particular older medication before treatment.
Not established
Episodic or pediatric migraine
- Safety and effectiveness are not established for episodic migraine with 14 or fewer headache days per month.
- For chronic migraine, safety and effectiveness are not established below age 18; an adolescent trial did not establish efficacy.1
Why a headache diary matters: Many people count only their most severe attacks and unintentionally undercount milder headache days. Recording every headache day, migraine-feature day, acute-medication day, and disabled day helps confirm the diagnosis and measure whether treatment is worthwhile.
How onabotulinumtoxinA may prevent migraine
The exact migraine-prevention mechanism is not completely established, and it should not be reduced to either “muscle relaxation” or a single pain molecule.
OnabotulinumtoxinA enters susceptible nerve terminals and cleaves SNAP-25, a protein needed for neurotransmitter-containing vesicles to release their contents. At the neuromuscular junction, this inhibits acetylcholine release and produces a local reduction in muscle activity.1
In chronic migraine, laboratory and translational evidence also supports an effect on peripheral sensory nerve endings. The leading model is that treatment reduces the release or surface trafficking of pain-related signaling molecules and receptors, thereby decreasing nociceptive input from trigeminal and upper-cervical pathways. With less ongoing peripheral input, central pain networks may become less sensitized over time. This is a biologically plausible model—not proof that every individual benefit comes from one specific molecular pathway.5
Relationship to CGRP treatments: Botox and CGRP-targeting medications have different pharmacological actions. They may be used sequentially or, for selected patients with persistent disability, together. A complementary or synergistic effect is plausible, but combination evidence remains largely observational rather than definitive randomized-trial evidence.8
What the PREEMPT trials actually showed
The pivotal studies support a real average benefit, while also showing a substantial placebo response and meaningful variation from patient to patient.
The pooled double-blind PREEMPT program compared onabotulinumtoxinA with placebo over 24 weeks in adults with chronic migraine.3
At week 24, average headache days per 28-day period decreased by 8.4 days with onabotulinumtoxinA and 6.6 days with placebo—an average treatment difference of 1.8 headache days beyond placebo. Disability and quality-of-life measures also improved more with active treatment.3
How to interpret this: these are group averages, not a promise. Some patients improve substantially, some modestly, and some do not respond.
One cycle may not tell the whole story. A PREEMPT post hoc analysis found that some patients who did not meet response thresholds after the first cycle became responders during the second or third cycle. When treatment is tolerated and clinically appropriate, response is often judged over more than one 12-week cycle rather than after the first injections alone.4
What to expect during a course of treatment
A standardized procedure works best when it is paired with a clear baseline, careful anatomy, and objective follow-up.
Confirm the diagnosis and baseline
Review headache pattern, associated symptoms, acute-medication use, prior preventive treatments, neurological examination, and relevant red flags. A diary provides the baseline against which response will be judged.
Review safety and medications
Discuss prior botulinum toxin exposure, allergies, infection at injection sites, swallowing or breathing problems, neuromuscular disease, pregnancy or breastfeeding, blood thinners, aminoglycoside antibiotics, muscle relaxants, and other relevant medicines.
Receive the injections
The U.S. prescribing information recommends 155 Units divided among 31 sites in seven muscle areas: frontalis, corrugator, procerus, temporalis, occipitalis, cervical paraspinal muscles, and trapezius. The visit usually does not require sedation.1
Track benefit and repeat at 12 weeks
Some people notice change during the first several weeks, but benefit is assessed over the full cycle. The labeled retreatment schedule is every 12 weeks. Frequency, severity, disability, acute-medication use, and side effects should all be reviewed—not headache days alone.
155 Units versus 195 Units: The current U.S. prescribing information recommends 155 Units at 31 fixed sites. The PREEMPT trials permitted 155–195 Units, including optional “follow-the-pain” sites, and some clinicians or payer policies use that broader range. Dose and sites should be individualized by a clinician trained in the PREEMPT anatomy; BOTOX Units are product-specific and cannot be converted directly to units of another botulinum toxin.16
Common side effects, important cautions, and urgent warning signs
Most adverse effects in the chronic-migraine trials were localized and temporary, but botulinum toxin has clinically important contraindications and a boxed warning.
| Adverse reaction | BOTOX 155–195 Units | Placebo | What patients may notice |
|---|---|---|---|
| Neck pain | 9% | 3% | Soreness, tightness, or discomfort in the neck. |
| Headache | 5% | 3% | Headache reported as an adverse event after treatment. |
| Migraine | 4% | 3% | Worsening or recurrence of migraine; severe worsening requiring hospitalization occurred in about 1% versus 0.3% with placebo, usually during the first week. |
| Eyelid droop (ptosis) | 4% | <1% | Temporary drooping of an eyelid; brow or forehead appearance can also change. |
| Muscular weakness | 4% | <1% | Local weakness, often involving injected or nearby muscles. |
| Musculoskeletal stiffness | 4% | 1% | Temporary stiffness in treated head and neck regions. |
| Injection-site pain | 3% | 2% | Brief tenderness, soreness, or bruising. |
Rates above come from the two placebo-controlled chronic-migraine trials in the U.S. prescribing information. Trial rates do not predict an individual patient's risk.1
Do not treat
Label contraindications
- Known hypersensitivity to any botulinum toxin product or formulation component.
- Infection at a proposed injection site.1
Extra caution
Conditions and medicines to disclose
- Myasthenia gravis, Lambert-Eaton syndrome, ALS, peripheral motor neuropathy, or another neuromuscular disorder.
- Existing swallowing or breathing difficulty.
- Another botulinum toxin product within recent months.
- Aminoglycoside antibiotics, medicines that interfere with neuromuscular transmission, or muscle relaxants.
- Pregnancy, plans for pregnancy, or breastfeeding; human data are limited.1
Boxed warning—distant spread of toxin effect: Botulinum toxin effects can rarely be seen beyond the injection area, with symptoms such as generalized weakness, double vision, eyelid droop, difficulty speaking, swallowing, or breathing. Symptoms have been reported hours to weeks after injection. The Medication Guide states that no confirmed serious case of distant spread has been reported at the recommended chronic-migraine dose, but the boxed warning still applies. Seek immediate medical attention for breathing, swallowing, or speech difficulty, or significant generalized weakness.1
Botox is one part of a complete chronic-migraine plan
Treatment selection should reflect the patient's diagnosis, disability, prior response, medical history, preferences, and access—not a one-size-fits-all hierarchy.
May be a reasonable option
When chronic migraine remains burdensome
- The chronic-migraine pattern is confirmed and headaches remain frequent or disabling.
- Oral prevention has not helped, caused unacceptable side effects, is contraindicated, or is not preferred.
- A treatment given every 12 weeks is preferable to a daily medication.
- Medication-overuse headache or other contributors are being identified and addressed as part of the same plan.
Other modern options
Prevention can be layered or changed
- Established oral preventives, selected according to comorbidities and safety.
- CGRP monoclonal antibodies and preventive gepants, which the American Headache Society recognizes as first-line preventive options.7
- Behavioral treatment, sleep and lifestyle regularity, physical therapy when relevant, and noninvasive neuromodulation.
- Combination prevention for selected patients who remain substantially disabled, with benefit and coverage reassessed over time.
Insurance rules are not the same as the FDA indication
The FDA label does not require failure of a specified number of older preventives. Medicare contractors and commercial plans may nevertheless require documentation of chronic-migraine frequency and duration, disability, prior preventive trials or contraindications, and continued benefit. Requirements differ by plan and can change. A complete diary and medication history can reduce avoidable delays.9
Frequently asked questions
These answers provide general context; the appropriate plan depends on an individual evaluation.
Is migraine Botox the same as cosmetic Botox?
The active product is onabotulinumtoxinA, but medical migraine treatment uses a defined preventive indication, dose, anatomical pattern, and follow-up plan. Some forehead movement or appearance may change temporarily because several injection sites are in the forehead and brow region, but cosmetic treatment is not the purpose of the migraine protocol.
How quickly should I expect a result?
Some patients notice change during the first several weeks. A first cycle may reduce attack intensity or improve response to acute medication before producing a large change in headache-day count. Because some later responders improve during cycles 2 or 3, treatment is often evaluated over more than one cycle when it is safe, tolerated, and clinically appropriate.
Can Botox be used with a CGRP antibody or preventive gepant?
Sometimes. Combination prevention may be considered when a single treatment leaves substantial migraine burden. Evidence supporting Botox plus a CGRP monoclonal antibody is mainly observational and expert-consensus based, not a definitive large randomized trial. Safety, cost, and insurer requirements should be reviewed individually.8
What if I have fewer than 15 headache days each month?
The safety and effectiveness of BOTOX have not been established for prevention of episodic migraine with 14 or fewer headache days per month. Other preventive options—including CGRP-targeting therapies and selected oral medications—may be appropriate depending on attack frequency, disability, medical history, and patient preference.1
Can I receive treatment while pregnant or breastfeeding?
The U.S. label states that adequate human pregnancy data are not available, and there are no data on the presence of BOTOX in human or animal milk, effects on a breastfed infant, or effects on milk production. The decision requires individualized discussion of the migraine burden, alternatives, timing, and uncertainty.1
Should I stop blood thinners or other medicines before injections?
Do not stop a prescription medicine on your own. Provide a complete medication list before treatment. Blood-thinning medication may increase bruising, while certain antibiotics, muscle relaxants, and medicines affecting neuromuscular transmission may change botulinum toxin effects. The treating clinician and prescribing clinician should coordinate any needed plan.
How do we decide whether to continue?
Response should be measured against a baseline diary: headache and migraine days, severity, disabled hours or days, acute-medication use, emergency visits, and function. A meaningful benefit may involve fewer days, milder attacks, shorter attacks, better response to rescue medication, or improved function. Continued treatment should be reassessed rather than renewed automatically.
Considering Botox for chronic migraine?
The first step is confirming the headache diagnosis and establishing an accurate baseline. We can then compare Botox with other preventive options and build a plan around your pattern, medical history, goals, and access.
References
- U.S. National Library of Medicine. BOTOX (onabotulinumtoxinA) U.S. Prescribing Information and Medication Guide. DailyMed. Current label accessed July 10, 2026.
- Headache Classification Committee of the International Headache Society. 1.3 Chronic migraine. International Classification of Headache Disorders, 3rd edition.
- Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921-936. doi:10.1111/j.1526-4610.2010.01678.x.
- Silberstein SD, Dodick DW, Aurora SK, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86(9):996-1001. doi:10.1136/jnnp-2013-307149.
- Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache. 2020;60(7):1259-1272. doi:10.1111/head.13849.
- Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache. 2017;57(5):766-777. doi:10.1111/head.13074.
- Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333-341. doi:10.1111/head.14692.
- Ailani J, Blumenfeld AM. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache. 2022;62(1):106-108. doi:10.1111/head.14244.
- American Headache Society. Updated Botulinum Toxin A Local Coverage Determination Policy. February 22, 2026.
BOTOX® is a registered trademark of Allergan, an AbbVie company. Mention of a brand name identifies the product discussed and does not imply manufacturer sponsorship of this page.
Medical disclaimer. This article is provided for general educational and informational purposes only. It does not constitute individualized medical advice, diagnosis, treatment, a recommendation for any specific test or therapy, or informed consent. Medical information changes over time, and this article may not reflect developments occurring after its stated review date or apply to your individual circumstances. Do not disregard or delay professional medical advice, or start, stop, or change any medication or treatment, based on this article. Discuss personal medical decisions with a qualified healthcare professional who can evaluate your individual history and circumstances. Accessing or using this website does not, by itself, create a physician–patient relationship with Los Altos Neurology or any of its clinicians. Do not use this website for urgent or emergency medical concerns; call 911 or seek immediate emergency care. Although Los Altos Neurology makes reasonable efforts to provide accurate and current information, it does not guarantee that all content is complete, current, or applicable to every individual. See our full Medical Disclaimer.